Complement System
The complement system is a sophisticated network of more than 30 circulating and membrane-bound proteins that constitutes a primary pillar of the innate immune system in vertebrates. Primarily synthesized in the liver and secreted into the blood and interstitial fluids, these proteins exist as inactive precursors (zymogens) that are activated through a series of proteolytic cleavage events. This biochemical cascade allows for a rapid, amplified response to pathogens, providing a critical first line of defense that operates independently of the adaptive immune system's requirement for prior antigen exposure.
The system functions by "complementing" the activity of antibodies and phagocytic cells. Its primary objectives are the identification and neutralization of pathogens, the recruitment of inflammatory cells to the site of infection, and the clearance of apoptotic cellular debris and immune complexes. By tagging foreign cells for destruction—a process known as opsonization—and inducing direct lysis of target membranes, the complement system prevents systemic infections and maintains homeostatic balance.
Dysregulation of the complement system can lead to significant clinical pathology. Under-activation or genetic deficiencies may increase susceptibility to pyogenic infections or lead to the accumulation of immune complexes, contributing to autoimmune conditions such as systemic lupus erythematosus (SLE). Conversely, over-activation or a failure in regulatory mechanisms can result in the accidental destruction of host tissues, manifesting in disorders such as hereditary angioedema or atypical hemolytic uremic syndrome (aHUS).
Activation Pathways
The complement system is activated through three distinct biochemical pathways, each recognizing different molecular triggers. While the initiation mechanisms differ, all three pathways converge at the cleavage of C3, the most abundant complement protein, which serves as the central hub of the system.
Classical Pathway
The classical pathway is typically triggered by the formation of antigen-antibody complexes. When IgM or IgG antibodies bind to a surface antigen, the C1 complex—composed of one C1q molecule and two molecules each of the serine proteases C1r and C1s—binds to the Fc region of the antibody. This activates C1s, which subsequently cleaves C4 and C2. The resulting fragments combine to form the C3 convertase ($C4b2a$), which then cleaves C3 into C3a and C3b.
Lectin Pathway
The lectin pathway is antibody-independent and relies on pattern recognition receptors (PRRs). Soluble proteins, such as mannose-binding lectin (MBL) or ficolins, recognize and bind to specific carbohydrate patterns (such as mannose) common on the surfaces of bacteria and fungi. This binding activates MBL-associated serine proteases (MASPs), which mirror the classical pathway by cleaving C4 and C2 to form the $C4b2a$ C3 convertase.
Alternative Pathway
The alternative pathway serves as a continuous surveillance mechanism. It is characterized by the spontaneous hydrolysis of C3 in the plasma, a process termed "tick-over." This produces a small amount of $C3(H_2O)$, which can bind Factor B. Once Factor B is cleaved by Factor D, the resulting complex ($C3bBb$) acts as the alternative C3 convertase. Because C3b produced by any of the three pathways can initiate this loop, the alternative pathway functions as an amplification mechanism for the entire system.
Effector Functions
Once the C3 convertase is formed, the system executes three primary effector functions to neutralize the identified threat.
Opsonization
The cleavage of C3 produces C3b, which covalently attaches to the surface of the pathogen. C3b acts as an opsonin, a molecular tag that "primes" the pathogen for destruction. Phagocytic cells, including macrophages and neutrophils, possess specific C3b receptors. When these cells encounter a C3b-coated microbe, they bind to the tag and engulf the pathogen via phagocytosis.
Inflammation and Chemotaxis
Small peptide fragments released during the cascade, specifically C3a and C5a, are known as anaphylatoxins. These molecules bind to receptors on mast cells and basophils, triggering the release of histamine. This increases vascular permeability and recruits other leukocytes to the site of infection. C5a, in particular, acts as a potent chemoattractant, guiding neutrophils toward the highest concentration of the protein at the infection site.
Lysis and the Membrane Attack Complex (MAC)
The final stage of the cascade is the formation of the Membrane Attack Complex (MAC). C5 convertase cleaves C5 into C5a and C5b. C5b recruits C6, C7, and C8, which then catalyze the polymerization of multiple C9 molecules. These C9 proteins insert themselves into the lipid bilayer of the target cell membrane, forming a transmembrane pore. This disrupts the osmotic balance of the cell, leading to an influx of water and ions, causing the cell to swell and eventually lyse. The effectiveness of the MAC varies depending on the thickness and composition of the target membrane; it is highly effective against Gram-negative bacteria but less so against Gram-positive bacteria with thick peptidoglycan layers.
Regulation and Control
Because the complement system is potentially destructive to host tissues, it is strictly regulated by soluble and membrane-bound proteins to prevent "innocent bystander" damage to healthy cells.
Soluble Regulators
Soluble regulators circulate in the plasma to inhibit the activation of the cascade in the absence of a pathogen.
* C1 Inhibitor (C1-INH): This protein dissociates C1r and C1s from C1q, effectively halting the classical pathway. A deficiency in C1-INH leads to hereditary angioedema.
* Factor H: The primary regulator of the alternative pathway, Factor H competes with Factor B for binding to C3b and accelerates the decay of the $C3bBb$ complex.
Membrane-Bound Regulators
Host cells express specific proteins on their surfaces to ensure they are not targeted by the MAC or convertases.
* Decay-Accelerating Factor (DAF/CD55): Found on the surface of host cells, DAF rapidly dissociates C3 convertases, preventing the cascade from propagating on self-surfaces.
* CD59 (Protectin): This membrane protein prevents the final polymerization of C9, thereby blocking the completion of the MAC and protecting the host cell from lysis.
Clinical Significance and Therapeutics
Genetic deficiencies and pharmacological interventions in the complement system provide critical insights into human immunology and disease.
Genetic Deficiencies
Deficiencies in specific complement proteins correlate with distinct clinical phenotypes. For example, individuals lacking C2 or C4 are at a significantly higher risk for developing systemic lupus erythematosus (SLE) due to an impaired ability to clear immune complexes. Deficiencies in the late-stage components (C5–C9) often lead to recurrent infections by Neisseria species, as the MAC is essential for killing these specific bacteria.
Pharmacological Targeting
Precision medicine now utilizes the complement system as a therapeutic target. Monoclonal antibodies and small molecule inhibitors are used to treat rare diseases. Eculizumab, a humanized monoclonal antibody, binds to C5, preventing the formation of the MAC and the release of C5a. This drug is used to treat Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
See also
References
- Janeway, C. A., et al. (2001). "The Complement System." Immunobiology: The Immune System in Health and Disease.
- Merle, N., et al. (2015). "Complement System Protein Sequence and Structure." Journal of Immunology Research.
- Ricklin, D., et al. (2010). "Complement: A Key System for Immune Defense and Homeostasis." Nature Reviews Immunology.
- Abbas, A. K., & Lichtman, A. H. (2021). Cellular and Molecular Immunology. Elsevier.